Arecor Therapeutics Past Earnings Performance
Past criteria checks 0/6
Arecor Therapeutics's earnings have been declining at an average annual rate of -24.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 32.8% per year.
Key information
-24.9%
Earnings growth rate
-11.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 32.8% |
| Return on equity | -170.7% |
| Net Margin | -176.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Arecor Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 5 | -9 | 9 | 5 |
| 31 Mar 24 | 5 | -9 | 9 | 6 |
| 31 Dec 23 | 5 | -9 | 9 | 6 |
| 30 Sep 23 | 4 | -9 | 9 | 6 |
| 30 Jun 23 | 3 | -9 | 8 | 7 |
| 31 Mar 23 | 3 | -9 | 7 | 8 |
| 31 Dec 22 | 2 | -9 | 5 | 9 |
| 30 Sep 22 | 2 | -8 | 4 | 8 |
| 30 Jun 22 | 1 | -7 | 2 | 8 |
| 31 Mar 22 | 1 | -7 | 2 | 7 |
| 31 Dec 21 | 1 | -6 | 2 | 5 |
| 30 Sep 21 | 1 | -5 | 2 | 5 |
| 30 Jun 21 | 1 | -5 | 2 | 4 |
| 31 Mar 21 | 2 | -4 | 2 | 4 |
| 31 Dec 20 | 2 | -3 | 2 | 4 |
| 31 Dec 19 | 2 | -2 | 2 | 4 |
| 31 May 19 | 1 | -2 | 1 | 3 |
| 31 May 18 | 1 | -1 | 1 | 2 |
Quality Earnings: 6UI is currently unprofitable.
Growing Profit Margin: 6UI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6UI is unprofitable, and losses have increased over the past 5 years at a rate of 24.9% per year.
Accelerating Growth: Unable to compare 6UI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6UI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Return on Equity
High ROE: 6UI has a negative Return on Equity (-170.66%), as it is currently unprofitable.